Presentation

Company Profile
Sedana Medical is a drug delivery/pharma company founded in 2005 after acquiring the AnaConDa technology from Teleflex. AnaConDa enables safe and simple delivery of volatile anaesthetics to invasively ventilated patients in the ICU setting. The AnaConDa device has CE mark in Europe, and the candidate drug Sedaconda (isoflurane) was recently approved through the decentralized European procedure by the German Medicines Agency. Due to high customer demand, the technology has been used off-label for several years.

Recent highlights
In July, Sedana announced the regulatory approval in Europe, a quarter ahead of expectations. Soon after, the first national approval was received in France. Despite tough comps, Sedana managed to deliver organic sales growth of 3% in Q2. Opex was significantly higher than expected as the company is building its commercialization organization ahead of European launch in H2 2021/H2 2022.

Outlook
A number of significant news items are expected during H2 2021, with the full publication of results from the SED001 study, IND filing in the US, several national approvals, Chinese approval and initial SEK 13m order and possible interim results from the SESAR study, as some highlights. We feel confident about the company’s chances of reaching its 10% market penetration target and sales of SEK 500m in Europe three years after the registration approval.